Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | BCDIN3D | Q7Z5W3 | 7/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.35 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25787980 | 0.92 | JAK2 (0.33) | JAK2JAK3PTK2TAS2R14BCDIN3D | |
| SCHEMBL20553223 | 0.81 | DHODH (0.42) | ABCG2ABCB1 | |
| SCHEMBL20552244 | 0.81 | JAK2 (0.39) | JAK2JAK3PTK2TAS2R14BCDIN3D | |
| SCHEMBL20552425 | 0.80 | TEAD1 (0.38) | JAK2JAK3PTK2BCDIN3DBRAF | |
| SCHEMBL20552512 | 0.78 | TEAD1 (0.38) | JAK2JAK3PTK2TAS2R14BCDIN3D | |
| SCHEMBL20552323 | 0.78 | PKM (0.37) | JAK2JAK3PTK2BCDIN3DBRAF | |
| SCHEMBL20552643 | 0.76 | ABCG2 (0.47) | TAS2R14ABCG2ABCB1 | |
| SCHEMBL20552347 | 0.75 | ABCG2 (0.46) | TAS2R14ABCG2ABCB1 | |
| SCHEMBL21764978 | 0.74 | JAK2 (0.36) | JAK2JAK3PTK2TAS2R14BRAF | |
| SCHEMBL25787985 | 0.74 | JAK2 (0.33) | JAK2JAK3PTK2TAS2R14BCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | JAK2 1879/4885JAK3 3012/4885PTK2 380/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | JAK2 1879/4885JAK3 3012/4885PTK2 380/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | JAK2 4672/4885JAK3 4440/4885PTK2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.